Identifying and investigating new treatments to improve patient outcomes
We are using our unique expertise and technologies to develop innovative antibody-based molecular concepts in immuno-oncology
Our discovery platform enables us to develop best-in-class therapeutic antibodies in auto-immune and inflammatory disease
We are developing novel drug concepts in anaemia of chronic disease and other blood diseases
We are building a rich pipeline of assets in four main therapeutic spaces: immuno-oncology, inflammation, haematology and infectious diseases. Our most advanced assets entered development in 2015 with first proof of concepts scheduled for readout by 2019.Download Pipeline PDF
Kymab's data at the November 2017 Society for Immunotherapy of Cancer meeting on its lead immuno-oncology antibody KY1044, showing strong potential for inhibiting tumour growth
2017 British Society for Immunology Congress poster showing that T-cells generated by Kymab's co-culture system can provide a suitable setting for evaluation of potential patient responses to immunotherapy
At the 2017 British Society for Immunology Congress, Kymab's team describe a cell-based, in vitro screening cascade to characterise anti-human PD-L 1 antibodies, identifying a lead clone, KY1003, that has the attributes of a clinically relevant PD-L1 antibody
The Kymab team developed a "tumour-educated" T-cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies: data presented at the 2017 British Society for Immunology Congress shows how KY1003 can revert T-cell exhaustion in in vitro models.
At the April 2018 American Association for Cancer Research Annual meeting, Kymab's team show that combining immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response, warranting the assessment of KY1044 in cancer patients in a clinical trial
Kymab's data reports that KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo: the results, presented at the April 2018 American Association for Cancer Research Annual meeting, support development of KY1055 for the treatment of solid tumours
Published in Nature Biotechnology in March 2014, the paper by Kymab scientists describes the development of Kymouse, which is able to produce an enormous range of human antibodies that can be developed as potent drugs to treat diseases such as cancer, autoimmune and infectious diseases.
Kymab and Seattle Children’s Research Institute publish impressive results in Science Translational Medicine using KY1005 in a model of acute Graft-versus-Host Disease (aGVHD), suggesting an important role in blood-system transplants, such as in the treatment of leukaemia.